Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma

High‐risk neuroblastoma, a predominantly TP53 wild‐type (wt) tumour, is incurable in >50% patients supporting the use of MDM2 antagonists as novel therapeutics. Idasanutlin (RG7388) shows in vitro synergy with chemotherapies used to treat neuroblastoma. This is the first study to evaluate the in...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Lindi, Pastorino, Fabio, Berry, Philip, Bonner, Jennifer, Kirk, Calum, Wood, Katrina M., Thomas, Huw D., Zhao, Yan, Daga, Antonio, Veal, Gareth J., Lunec, John, Newell, David R., Ponzoni, Mirco, Tweddle, Deborah A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6491995/
https://www.ncbi.nlm.nih.gov/pubmed/30536898
http://dx.doi.org/10.1002/ijc.32058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6491995/
https://www.ncbi.nlm.nih.gov/pubmed/30536898
http://dx.doi.org/10.1002/ijc.32058

Ejemplares similares